Cell And Gene Therapy Videos

  1. CDMO SOWs Must (Re-)Align With New Project Realities 6/26/2025

    Decades of experience in cell and gene therapy outsourcing have taught Donna Rill, Chief Technology Officer, Triumvira Immunologics, that the key to success is ensuring CDMOs and sponsors understand the need to continuously align SOWs with the variances as projects move forward.

  2. Budgeting Key Component In Biologics Flexibility At CDMOs 6/26/2025

    You want flexibility in scheduling, contracts, and the entire CDMO relationship. While money can't buy you love, it can go a long way in getting that more flexible partnership.

  3. An Intro To CDMO Flexibility 6/26/2025

    Seshu Tummala, Executive Director at Uniquity Bio discusses some of the components of "CDMO flexibility" when it comes to biologics outsourcing relationships.

  4. Outsourcing Biologics Comes With "Demands" 6/26/2025

    Chief Editor Louis Garguilo opens the discussion with our panelists on the state of biologics outsourcing, and the "must haves" for sponsors of their CDMOs.

  5. Here's Where CDMOs Improve For Cell And Gene Therapy Customers? 6/26/2025

    Donna Rill, Chief Technology Officer, Triumvira Immunologics, has advice for CDMOs to improve their service to CGT customers, and conversely, where drug developers can improve as well.

  6. Scaling Up Your E. Coli pDNA Process From Parameter Screening To Pilot Scale 6/26/2025

    Discover a systematic approach to scalable plasmid DNA production using E. coli OneShot Top10, which features DOE-driven optimization and key insights for efficient biomanufacturing success.

  7. Navigating The Complex Landscape Of Lentiviral Vector Quality Control 6/26/2025

    Explore the latest in lentiviral vector release testing, which covers biosafety, regulatory insights, and QC strategies to ensure patient safety and accelerate your path to clinic.

  8. Accelerate Your AAV Journey To IND And Beyond 6/26/2025

    Explore essential QC strategies in AAV gene therapy and learn how to address rcAAV detection, viral clearance per ICH Q5A, and impurity profiling using NGS to meet evolving regulatory demands.

  9. UpTempo℠: Seamless Transitions From Bench To CGT Applications 6/19/2025

    Accelerate cell and gene therapy development with high-yield, regulatory-compliant plasmid DNA manufacturing that shortens timelines, minimizes risks, and streamlines your supply chain.

  10. Connecting Manufacturers And Providers To The Services Needed For Full End-To-End Patient And Order Management 6/16/2025

    Streamline complex cell and gene therapy logistics with an integrated platform that connects manufacturers with vital services, providing full visibility and control for a more efficient and successful patient journey.